[HTML][HTML] Inhibition of IL-17 ameliorates keratinocyte-borne cytokine responses in an in vitro model for house-dust-mite triggered atopic dermatitis
J Haertlé, P Kienlin, G Begemann, T Werfel… - Scientific Reports, 2023 - nature.com
A subgroup of patients suffering from atopic dermatitis (AD) does not respond to biologics
therapy targeting the key players of type-2 inflammation, and it is an ongoing discussion …
therapy targeting the key players of type-2 inflammation, and it is an ongoing discussion …
Inhibition of IL-17 ameliorates keratinocyte-borne cytokine responses in an in vitro model for house-dust-mite triggered atopic dermatitis
J Haertlé, P Kienlin, G Begemann, T Werfel… - Scientific …, 2023 - ui.adsabs.harvard.edu
A subgroup of patients suffering from atopic dermatitis (AD) does not respond to biologics
therapy targeting the key players of type-2 inflammation, and it is an ongoing discussion …
therapy targeting the key players of type-2 inflammation, and it is an ongoing discussion …
Inhibition of IL-17 ameliorates keratinocyte-borne cytokine responses in an in vitro model for house-dust-mite triggered atopic dermatitis.
J Haertlé, P Kienlin, G Begemann, T Werfel… - Scientific …, 2023 - europepmc.org
A subgroup of patients suffering from atopic dermatitis (AD) does not respond to biologics
therapy targeting the key players of type-2 inflammation, and it is an ongoing discussion …
therapy targeting the key players of type-2 inflammation, and it is an ongoing discussion …
[HTML][HTML] Inhibition of IL-17 ameliorates keratinocyte-borne cytokine responses in an in vitro model for house-dust-mite triggered atopic dermatitis
J Haertlé, P Kienlin, G Begemann, T Werfel… - Scientific …, 2023 - ncbi.nlm.nih.gov
A subgroup of patients suffering from atopic dermatitis (AD) does not respond to biologics
therapy targeting the key players of type-2 inflammation, and it is an ongoing discussion …
therapy targeting the key players of type-2 inflammation, and it is an ongoing discussion …
Inhibition of IL-17 ameliorates keratinocyte-borne cytokine responses in an in vitro model for house-dust-mite triggered atopic dermatitis.
J Haertlé, P Kienlin, G Begemann, T Werfel… - Scientific …, 2023 - search.ebscohost.com
A subgroup of patients suffering from atopic dermatitis (AD) does not respond to biologics
therapy targeting the key players of type-2 inflammation, and it is an ongoing discussion …
therapy targeting the key players of type-2 inflammation, and it is an ongoing discussion …
Inhibition of IL-17 ameliorates keratinocyte-borne cytokine responses in an in vitro model for house-dust-mite triggered atopic dermatitis
J Haertlé, P Kienlin, G Begemann… - Scientific …, 2023 - pubmed.ncbi.nlm.nih.gov
A subgroup of patients suffering from atopic dermatitis (AD) does not respond to biologics
therapy targeting the key players of type-2 inflammation, and it is an ongoing discussion …
therapy targeting the key players of type-2 inflammation, and it is an ongoing discussion …
Inhibition of IL-17 ameliorates keratinocyte-borne cytokine responses in an in vitro model for house-dust-mite triggered atopic dermatitis.
J Haertlé, P Kienlin, G Begemann, T Werfel… - Scientific …, 2023 - europepmc.org
A subgroup of patients suffering from atopic dermatitis (AD) does not respond to biologics
therapy targeting the key players of type-2 inflammation, and it is an ongoing discussion …
therapy targeting the key players of type-2 inflammation, and it is an ongoing discussion …
Inhibition of IL-17 ameliorates keratinocyte-borne cytokine responses in an in vitro model for house-dust-mite triggered atopic dermatitis.
J Haertlé, P Kienlin, G Begemann, T Werfel… - Scientific …, 2023 - search.ebscohost.com
A subgroup of patients suffering from atopic dermatitis (AD) does not respond to biologics
therapy targeting the key players of type-2 inflammation, and it is an ongoing discussion …
therapy targeting the key players of type-2 inflammation, and it is an ongoing discussion …